Forskning ved Københavns Universitet - Københavns Universitet


Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • L. Boccon-Gibod
  • P. Iversen
  • B.E. Persson
  • Laurent Boccon-Gibod
  • Peter Iversen
  • Bo-Eric Persson
Gonadotrophin-releasing hormone (GnRH) receptor blockers (antagonists) are the latest addition to the hormonal therapy armamentarium for patients with prostate cancer. In contrast to the GnRH agonists, GnRH blockers have an immediate onset of action and do not cause an initial surge in testosterone levels that can lead to clinical flare in patients with advanced disease. Degarelix (Firmagon is a new GnRH blocker that has recently been approved by the EMEA and US FDA for the treatment of men with hormone-sensitive advanced prostate cancer. In this article, we briefly review the Phase III trial data for degarelix 240/80 mg (licensed dose) versus leuprolide 7.5 mg that led to these recent approvals
Udgivelsesdato: 2009/12
TidsskriftExpert Review of Anticancer Therapy
Udgave nummer12
Sider (fra-til)1737-43
Antal sider7
StatusUdgivet - 1 dec. 2009

ID: 19596524